![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Keytruda Reduces Risk of Relapse of Kidney Cancer in Trials
Keytruda Reduces Risk of Relapse of Kidney Cancer in Trials
![Merck_logo.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/Merck_logo.jpg?t=1576126512&width=430)
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) significantly reduced disease recurrence in patients with renal cell carcinoma following surgical kidney removal.
In a phase 3 study, Keytruda reduced the risk of disease relapse or death by 32 percent vs. placebo after a follow-up of more than two years, the company said. At two years, the estimated disease-free survival rate was 77.3 percent in the Keytruda arm vs. 68.1 percent in the placebo cohort.
The latest results make Keytruda the first immunotherapy to show a benefit for treating kidney cancer in an adjuvant setting, said the trial’s lead investigator, Toni Choueiri.
Keytruda earned global revenue of $14.4 billion in 2020.
Upcoming Events
-
21Oct